Photo from wikipedia
The National Institute for Health and Care Excellence (NICE) has recommended tivozanib as an option for treating adults with previously untreated advanced renal cell carcinoma, after the manufacturer agreed a… Click to show full abstract
The National Institute for Health and Care Excellence (NICE) has recommended tivozanib as an option for treating adults with previously untreated advanced renal cell carcinoma, after the manufacturer agreed a discount to make the cost lower than existing treatments even though the appraisal committee found it “likely to be less effective.” “The estimated costs savings are high enough to compensate for the estimated lower effectiveness,” said the final …
Keywords:
less effective;
recommends kidney;
likely less;
nice recommends;
cancer drug;
kidney cancer
Journal Title: British Medical Journal
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Medical Journal
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!